Dr. Mahavir Agarwal, MD, PhD
Claim this profileCentre for Addiction and Mental Health
Studies Insulin Resistance
Studies Type 2 Diabetes
5 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Mahavir Agarwal, MD, PhD is currently running
Metformin
for Antipsychotic-Induced Weight Gain in Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD. Exercise and diet interventions have limitations and may not be sufficient, requiring effective adjunctive pharmacological approaches to target obesity and related comorbidities in IDD. However, persons with IDD treated with antipsychotics are systematically excluded from clinical trials hindering development of evidence to help guide safe and effective treatment of these comorbidities. Moreover, evidence from other disorders cannot be extrapolated to IDD given inherent biological differences between disorders. This trial will address the identified gaps, which extend beyond cardiovascular morbidity and negatively impact psychosocial outcomes, in a hugely underserviced population.This is the the first RCT (randomized control trial) to examine the efficacy of metformin in overweight or obese adults with IDD who have experienced antipsychotic-induced weight gain. By generating efficacy data for a very accessible and scalable intervention, allows for guideline and implementation strategies to address a recalcitrant health problem.
Recruiting2 awards Phase 46 criteria
Antipsychotics
for Insulin Resistance in Females
Females treated with antipsychotics have higher rates of comorbid metabolic syndrome than males. Despite this, females have historically been excluded from many mechanistic studies due to confounding effects of menstrual cycles. Recent evidence suggests that brain insulin resistance may be an underlying mechanism through which antipsychotics may exert their metabolic side effects. This study seeks to investigate how brain insulin action differs in females according to their menstrual cycle phase, and how a high metabolic liability agent such as olanzapine might interrupt these differential insulin effects. Young healthy females will be given olanzapine and intranasal insulin to test how these treatment combinations change brain processes. Participants will be tested during both the first half of their menstrual cycle (follicular phase) and the second half of their cycle (luteal phase). The investigators predict that intranasal insulin will change MRI-based measures in females, in a comparable way to males, in the follicular phase only. Adding olanzapine will block these effects of insulin in females in the follicular phase. This investigation has the potential to generate new knowledge in an area of significant unmet need. Demonstrating that antipsychotics disrupt brain insulin action, evidenced by inhibition of recognized effects of insulin on neuroimaging measures, will provide novel insights into currently poorly understood mechanisms.
Recruiting0 awards N/A
More about Mahavir Agarwal, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Mahavir Agarwal, MD, PhD has experience with
- Olanzapine
- Insulin Lispro
- Humalog
- Saline Nasal Spray
- Intranasal Insulin
- Placebo
Breakdown of trials Mahavir Agarwal, MD, PhD has run
Insulin Resistance
Type 2 Diabetes
Menstruation
Hyperinsulinemia
Antipsychotics
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mahavir Agarwal, MD, PhD specialize in?
Mahavir Agarwal, MD, PhD focuses on Insulin Resistance and Type 2 Diabetes. In particular, much of their work with Insulin Resistance has involved treating patients, or patients who are undergoing treatment.
Is Mahavir Agarwal, MD, PhD currently recruiting for clinical trials?
Yes, Mahavir Agarwal, MD, PhD is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Mahavir Agarwal, MD, PhD has studied deeply?
Yes, Mahavir Agarwal, MD, PhD has studied treatments such as Olanzapine, Insulin Lispro, Humalog.
What is the best way to schedule an appointment with Mahavir Agarwal, MD, PhD?
Apply for one of the trials that Mahavir Agarwal, MD, PhD is conducting.
What is the office address of Mahavir Agarwal, MD, PhD?
The office of Mahavir Agarwal, MD, PhD is located at: Centre for Addiction and Mental Health, Toronto, Ontario M6J 1H3 Canada. This is the address for their practice at the Centre for Addiction and Mental Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.